机构：[1]Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Lymphoma, Peking University Cancer Hospital & Institute,Beijing, China[2]National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences (CAMS) and Peking Union Medical College (PUMC). Center for Cancer PrecisionMedicine, CAMS and PUMC, National Institute of Biological Sciences, Collaborative Innovation Center for Cancer Medicine, Beijing, People's Republic of China[3]Fujian Medical University Union Hospital, Fuzhou, China[4]Chongqing University Cancer Hospital & Chongqing Cancer Hospital, Chongqing, China[5]Jiangsu Cancer Hospital & Jiangsu Institute of Cancer Research, Nanjing, Jiangsu, China[6]Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China华中科技大学同济医学院附属协和医院[7]The General Hospital of Chinese People's Liberation Army, Beijing, China[8]The Affiliated Provincial Hospital of Anhui Medical University, Hefei, Anhui, China[9]Peking Union Medical College Hospital, Chinese Academy of Medical Sciences (CAMS) and Peking Union Medical College (PUMC), Beijing, China[10]The Fourth Hospital of Hebei Medical University, Shijiazhuang, China河北医科大学第四医院[11]Second Affiliated Hospital of Nanchang University, Nanchang, China[12]National Geriatric Medical Center, Beijing Hospital, Beijing, China[13]Cancer Hospital of the University of Chinese Academy of Sciences, Zhejiang Cancer Hospital, Zhejiang, Hangzhou, China浙江省肿瘤医院[14]Shanxi Cancer Hospital and the Affiliated Cancer Hospital of Shanxi Medical University, Taiyuan, Shanxi, China[15]Fujian Provincial Cancer Hospital, Fuzhou, Fujian, China[16]Affiliated Hospital of Guizhou Medical University, Guizhou Cancer Hospital, Guiyang, Guizhou, China[17]Hunan Cancer Hospital and the Affiliated Cancer Hospital of Xiangya School of Medicine, Changsha, Hunan, China[18]Xijing Hospital of Fourth Military Medical University, Xi'an, China[19]Key Laboratory of Cancer Prevention and Therapy, National Clinical Research Center for Cancer, Tianjin Medical University Cancer Institute & Hospital, Tianjin,China[20]The Fifth Medical Center of PLA General Hospital, Beijing, China[21]Sun Yat-Sen University Cancer Center, State Key Laboratory of Oncology in South China.Collaborative Innovation Center for Cancer Medicine, Guangzhou,Guangdong, China
BackgroundThe gastrointestinal (GI) tract is the second most frequent extranasal involvement site for ENKTL. This study aimed to explore the clinicopathological features, treatment models, survival outcomes, and prognosis of gastrointestinal ENKTL (GI-ENKTL). MethodsThe clinical data of GI-ENKTL patients were extracted from the China Lymphoma Collaborative Group (CLCG) database and were analyzed retrospectively. ResultsA total of 30 patients were enrolled, with a male/female ratio of 4:1 and a median age of 42 years. Twenty-nine patients received chemotherapy, of whom 15 patients received asparaginase-based (ASP-based) regimens. Moreover, seven received surgery and three received radiotherapy. The overall response an d complete remission rates were 50.0% and 30.0% for the whole cohort, 50.0% and 37.5% for patients treated with ASP-based regimens, and 50.0% and 25.0% for those treated with non-ASP-based regimens, respectively. The median follow-up was 12.9 months and the 1-year overall survival rate was 40.0% for the whole cohort. For those patients in an early stage, ASP-based regimens resulted in a superior 1-year progression-free survival rate compared to non-ASP-based regimens (100.0% vs. 36.0%, p = .07). However, ASP-based regimens did not improve survival in patients at an advanced stage. ConclusionGI-ENKTL still has a poor prognosis, even in the era of modern asparaginase-based treatment strategies.
基金：
National Natural Science Foundation of China [81870154, 81972807, 81670187, 81970179, 81700197]; Beijing Natural Science Foundation [7202025, 7202026]; Capital's Funds for Health Improvement and Research [2018-1-2151, 2020-2Z-2157]; Beijing Municipal Science & Technology Commission [Z181100001918019]; Beijing Municipal Administration of Hospitals' Ascent Plan [DFL20151001]; Science Foundation of Peking University Cancer Hospital [2020-5]; Key laboratory of Carcinogenesis and Translational Research, Ministry of Education/Beijing [08]; Beijing Xisike Clinical Oncology Research Foundation [Y-Young2020-0524]
第一作者机构：[1]Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Lymphoma, Peking University Cancer Hospital & Institute,Beijing, China
共同第一作者：
通讯作者：
通讯机构：[1]Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Lymphoma, Peking University Cancer Hospital & Institute,Beijing, China[2]National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences (CAMS) and Peking Union Medical College (PUMC). Center for Cancer PrecisionMedicine, CAMS and PUMC, National Institute of Biological Sciences, Collaborative Innovation Center for Cancer Medicine, Beijing, People's Republic of China[*1]Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Lymphoma, Peking University Cancer Hospital & Institute, Beijing, China.
推荐引用方式(GB/T 7714)：
Liu Jia-Xin,Liu Xin,Yang Yong,et al.Clinical characteristics, treatment, and survival of 30 patients with gastrointestinal natural killer/T-cell lymphoma[J].CANCER REPORTS.2023,6(5):doi:10.1002/cnr2.1800.
APA：
Liu, Jia-Xin,Liu, Xin,Yang, Yong,Liu, Wei-Ping,Wang, Ying...&Song, Yu-Qin.(2023).Clinical characteristics, treatment, and survival of 30 patients with gastrointestinal natural killer/T-cell lymphoma.CANCER REPORTS,6,(5)
MLA：
Liu, Jia-Xin,et al."Clinical characteristics, treatment, and survival of 30 patients with gastrointestinal natural killer/T-cell lymphoma".CANCER REPORTS 6..5(2023)
